The emergence and rapid spread of antibiotic resistance has driven the interest and efforts of many researchers towards developing alternate therapies. One of the promising alternative is the use of naturally occurring Antimicrobial Peptides (AMP). The AMPs are part of our innate immune system and are considered as a potential new class of drugs to combat antibiotic resistant pathogens.  Though more than 2000 AMPs have been discovered and synthetically developed, only a few have reached clinical trials or received FDA approvals.  The failure of most clinical trials using exogenous administration of AMPs is either the lack of efficacy due to their low stability or high toxicity of synthetic peptides.  In contrast to the existing strategies, we propose to exploit the innate immunity response of our body to counter infectious agents.  Our research has uncovered a novel pathway to induce and sustain the secretion of AMPs from skin keratinocytes.  This is helpful in two ways: 1. AMPs secreted from the body have minimal cytotoxicity/immune reactions, and can be induced in a local area; and 2. Cellular secretion of these AMPs can be kept constant, which will avoid their depletion due to degradation at the site of infection.  Compared to the traditional antibiotic regimen which would just inhibit microbial growth in the cutaneous infection, the alternative AMP induction approach could serve dual purpose of neutralising the bacteria and promoting wound-healing in the diabetic patients.